Evidence map›Paper›PMID 40596506›Full record

ArticleScientific reports2025

Multiomics analyses of gut microbiota and metabolites in people living with HIV before and during SARS-COV-2 infection.

Xuebin Tian, Yiwen Xie, Yulong Zhao, Xiangyun Lu, Nanping Wu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Microbiome-Metabolome Crosstalk as a Driver of COVID-19 Severity.Medical sciences (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuebin TianState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Medical Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yiwen XieState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Medical Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yulong ZhaoCell Biology Research Platform, Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China.
Xiangyun LuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Medical Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. present81@163.com.
Nanping WuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Medical Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. flwnp2013@163.com.

Funding

National Key Research and Development Program of China 2020YFE0204300National Key Research and Development Program of China 2023YFC2506004
6 · The paper itself

Abstract

People living with human immunodeficiency virus (HIV) (PLWH) might have an increased risk of developing coronavirus disease 2019 (COVID-19); however, the impact of their gut microbiota and metabolites on the progress of COVID-19 is unknown. Herein, we analyzed the temporal changes in the gut microbiota composition and metabolites of PLWH at baseline and during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed the gut microbiota and metabolites by integrating 16 S rRNA gene sequencing and liquid chromatography-mass spectrometry untargeted metabolomics of 36 PLWH at baseline and during SARS-CoV-2 infection periods. Significant changes in the composition of the gut microbiota and an increased ratio of Firmicutes/Bacteroidetes during SARS-CoV-2 infection, relative to the baseline, were observed. At the genus level, the abundances of Lactobacillus and Lactiplantibacillus decreased significantly. Furthermore, seven differentially enriched human metabolic pathways (including protein digestion and absorption, central carbon metabolism in cancer, aminoacyl-tRNA biosynthesis, mineral absorption, ABC transporters, arginine and proline metabolism, and phenylalanine metabolism) were identified by comparing the fecal metabolites at baseline and during SARS-CoV-2 infection. Spearman correlation analysis revealed close relationships between the two differentially abundant microbiota members and the five differentially abundant fecal metabolites that might affect specific human metabolic pathways.This study is the first to characterize the gut microbiota and metabolites in PLWH at baseline and during SARS-CoV-2 infection. The key microbiota and metabolites in the infection process were identified, providing new ideas for treatment.

Indexed as

COVID-19Gastrointestinal MicrobiomeHIV InfectionsAdultFecesFemaleHumansMaleMetabolomeMetabolomicsMiddle AgedMultiomicsRNA, Ribosomal, 16SSARS-CoV-2RNA, Ribosomal, 16SCoronavirus disease 2019CytokineFecal metabolitesGut microbiotaHuman immunodeficiency virus

Identifiers

PMID40596506
PMCPMC12219276

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.